

Zachary Scott Wallace

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9435564/publications.pdf>

Version: 2024-02-01

126
papers

8,660
citations

93792

39
h-index

54771

88
g-index

131
all docs

131
docs citations

131
times ranked

7468
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: Correspondence on SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease ™ by C<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e131-e131.	0.5	8
2	Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry by Sparks<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e158-e158.	0.5	3
3	Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis by van Vollenhoven<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178.	0.5	7
4	Assessing the Severity of COVID-19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning–Derived Chest Radiograph Scores. <i>Arthritis Care and Research</i> , 2023, 75, 657-666.	1.5	8
5	Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality. <i>Rheumatology</i> , 2023, 62, 716-725.	0.9	4
6	Response to: Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors ™ by Jovani<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e132-e132.	0.5	1
7	Response to: COVID-19 in patients with rheumatic diseases: what is the real mortality risk? ™ by Marques<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e135-e135.	0.5	3
8	COVID-19 severity in asthma patients: a multi-center matched cohort study. <i>Journal of Asthma</i> , 2022, 59, 442-450.	0.9	22
9	Kidney Transplantation and Cardiovascular Events Among Patients With End-stage Renal Disease Due to Lupus Nephritis: A Nationwide Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1829-1834.	1.5	5
10	Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2022, 49, 104-109.	1.0	5
11	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 289-291.	0.5	69
12	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	1.0	9
13	Lifetime Allergy Symptoms in IgG4-related Disease: A Case-control Study. <i>Arthritis Care and Research</i> , 2022, 74, 1188-1195.	1.5	13
14	Validation of Antineutrophil Cytoplasmic Antibody-associated Vasculitis as the Cause of End-stage Renal Disease in the US Renal Data System. <i>ACR Open Rheumatology</i> , 2022, 4, 8-12.	0.9	2
15	Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	0.9	6
16	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	2.9	117
17	Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2022, 4, e105-e112.	2.2	16
18	Derivation and Validation of Algorithms to Identify Patients With Immunoglobulin G4-related Disease Using Administrative Claims Data. <i>ACR Open Rheumatology</i> , 2022, . .	0.9	3

#	ARTICLE	IF	CITATIONS
19	Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy. <i>RMD Open</i> , 2022, 8, e002082.	1.8	9
20	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	2.2	30
21	The impact of COVID-19 on rheumatology trainingâ€”results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac001.	0.3	7
22	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
23	Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. <i>Rheumatology</i> , 2022, 61, SI151-SI156.	0.9	7
24	The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial. <i>Rheumatology and Therapy</i> , 2022, 9, 497-508.	1.1	1
25	Coronavirus Disease 2019 Outcomes Among Recipients of <sc>Antiâ€CD20</sc> Monoclonal Antibodies for <sc>Immuneâ€Mediated</sc> Diseases: A Comparative Cohort Study. <i>ACR Open Rheumatology</i> , 2022, 4, 238-246.	0.9	27
26	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150.	0.9	40
27	Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases. <i>Lancet Rheumatology</i> , The, 2022, , .	2.2	0
28	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	1.8	34
29	DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152025.	1.6	36
30	The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1438-1445.	0.5	7
31	CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 368-382.	1.5	53
32	Response to: â€COVID-19 in patients with rheumatological diseases treated with Anti-TNFâ€™ by Brito et al and â€Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China â€hot spotâ€™ versus in US â€hot spotâ€™: similarities and differencesâ€™ by Zhao et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e64-e64.	0.5	4
33	Association of Race and Ethnicity With COVIDâ€19 Outcomes in Rheumatic Disease: Data From the COVIDâ€19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380.	2.9	66
34	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , 2021, 60, 353-358.	0.9	32
35	Antirheumatic Disease Therapies for the Treatment of COVIDâ€19: A Systematic Review and Metaâ€Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	2.9	52
36	COVIDâ€19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 914-920.	2.9	117

#	ARTICLE	IF	CITATIONS
37	Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 660-666.	0.5	74
38	The Association Between Physician Gender and Career Advancement Among Academic Rheumatologists in the United States. <i>Arthritis and Rheumatology</i> , 2021, 73, 168-172.	2.9	17
39	The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.3-2.	0.5	14
40	Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 347-354.	2.9	25
41	Management of primary vasculitides with biologic and novel small molecule medications. <i>Current Opinion in Rheumatology</i> , 2021, 33, 8-14.	2.0	1
42	Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine. <i>JAMA Internal Medicine</i> , 2021, 181, 284.	2.6	7
43	Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e131-e137.	2.2	61
44	Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. <i>Genome Medicine</i> , 2021, 13, 35.	3.6	26
45	ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1060-1064.	1.0	5
46	COVID-19 and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2021, 33, 255-261.	2.0	32
47	Topic modeling to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A proof of concept study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 150-157.	1.6	5
48	The association of smoking with immunoglobulin G4-related disease: a case-control study. <i>Rheumatology</i> , 2021, 60, 5310-5317.	0.9	18
49	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. <i>Current Rheumatology Reports</i> , 2021, 23, 28.	2.1	15
50	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
51	Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 412-418.	2.0	6
52	Incident systemic rheumatic disease following COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e402-e404.	2.2	17
53	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021, 21, 1395-1401.	0.5	20
54	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	1.8	121

#	ARTICLE	IF	CITATIONS
55	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e638-e647.	2.2	30
56	Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. <i>ACR Open Rheumatology</i> , 2021, 3, 834-841.	0.9	9
57	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2021, 3, e707-e714.	2.2	40
58	Association of renal transplantation with reduced risk of myocardial infarction and ischemic stroke in ANCA-associated vasculitis: An observational cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1180-1185.	1.6	4
59	SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 817-819.	0.5	37
60	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.5	496
61	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
62	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864.	2.2	38
63	Case 37-2021: A 60-Year-Old Man with Fevers, Fatigue, Arthralgias, a Mouth Ulcer, and a Rash. <i>New England Journal of Medicine</i> , 2021, 385, 2282-2293.	13.9	1
64	Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2370.	3.8	4
65	Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e40-e40.	0.5	4
66	Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 1543-1549.	1.5	20
67	An 80-Year-Old Man With Fevers, Altered Mental Status, and Joint Effusions. <i>Arthritis Care and Research</i> , 2020, 72, 293-300.	1.5	1
68	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 201-202.	2.9	0
69	Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid. <i>Arthritis and Rheumatology</i> , 2020, 72, 234-241.	2.9	9
70	Disease Severity Linked to Increase in Autoantibody Diversity in IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 687-693.	2.9	38
71	All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. <i>Rheumatology</i> , 2020, 59, 2308-2315.	0.9	71
72	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 77-87.	0.5	390

#	ARTICLE	IF	CITATIONS
73	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 7-19.	2.9	292
74	Prostate and pancreas involvement are linked in IgG4-related disease. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1245-1251.	1.6	7
75	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
76	The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. <i>Rheumatology</i> , 2020, 59, 1204-1206.	0.9	34
77	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.5	908
78	Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot"™. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1156-1162.	0.5	217
79	Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 190-195.e2.	0.5	21
80	Management of ANCA associated vasculitis. <i>BMJ</i> , The, 2020, 368, m421.	3.0	54
81	Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis. <i>ACR Open Rheumatology</i> , 2020, 2, 261-268.	0.9	10
82	Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA Internal Medicine</i> , 2020, 180, 870.	2.6	28
83	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	2.2	172
84	Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , 2020, 7, S85-S88.	1.3	10
85	Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 736-745.e6.	1.5	123
86	Immunoglobulin G4-related Disease. <i>Clinics in Chest Medicine</i> , 2019, 40, 583-597.	0.8	42
87	Phospholipase A2 receptor-associated membranous nephropathy in a patient with IgG4-related disease. <i>Medicine (United States)</i> , 2019, 98, e15616.	0.4	9
88	171. Cardiovascular Disease is the Most Common Cause of Death in ANCA-Associated Vasculitis (AAV). <i>Rheumatology</i> , 2019, 58, .	0.9	2
89	172. The Association of Differences in Lipid Parameters with Disease Activity in ANCA-Associated Vasculitis (AAV). <i>Rheumatology</i> , 2019, 58, .	0.9	0
90	Renal Transplantation and Survival Among Patients With Lupus Nephritis. <i>Annals of Internal Medicine</i> , 2019, 170, 240.	2.0	48

#	ARTICLE	IF	CITATIONS
91	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	2.9	23
92	157-Contemporary prescription opioid use among patients with systemic lupus erythematosus: a population-based cohort study. , 2019, , .		0
93	Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?. <i>Frontiers in Immunology</i> , 2019, 10, 2855.	2.2	28
94	All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. <i>Arthritis and Rheumatology</i> , 2019, 71, 403-410.	2.9	38
95	Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 406-412.	0.5	248
96	An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. <i>Arthritis Care and Research</i> , 2018, 70, 1671-1678.	1.5	103
97	Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 288-292.	1.6	21
98	Improving Mortality in End-Stage Renal Disease Due to Granulomatosis With Polyangiitis (Wegener's) From 1995 to 2014: Data From the United States Renal Data System. <i>Arthritis Care and Research</i> , 2018, 70, 1495-1500.	1.5	10
99	Lymphomas in IgG4-related disease: clinicopathologic features in a Western population. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 839-852.	1.4	39
100	Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , 2018, 70, 445-453.	1.5	12
101	Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 394-402.	0.4	61
102	Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. <i>Medicine (United States)</i> , 2018, 97, e12631.	0.4	31
103	Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1333-1338.	0.5	13
104	Case 20-2018: A 64-Year-Old Man with Fever, Arthralgias, and Testicular Pain. <i>New England Journal of Medicine</i> , 2018, 378, 2518-2529.	13.9	1
105	Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 737-743.e3.	2.0	54
106	Case 15-2017 - A 27-Year-Old Woman with Anemia, Thrombocytosis, and Skin Lesions after Travel Abroad. <i>New England Journal of Medicine</i> , 2017, 376, 1973-1981.	13.9	2
107	Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies. <i>Arthritis and Rheumatology</i> , 2017, 69, 1722-1732.	2.9	46
108	Atypical IgG4+ Plasmacytic Proliferations and Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 215-235.	0.4	18

#	ARTICLE	IF	CITATIONS
109	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	1.5	11
110	Nationwide Trends in Hospitalizations and In-Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2017, 69, 915-921.	1.5	32
111	Association of IgG4-Related Disease With History of Malignancy. <i>Arthritis and Rheumatology</i> , 2016, 68, 2283-2289.	2.9	90
112	Large vessel involvement by IgG4-related disease. <i>Medicine (United States)</i> , 2016, 95, e3344.	0.4	132
113	Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 825-838.	1.5	306
114	Predictors of disease relapse in IgG4-related disease following rituximab. <i>Rheumatology</i> , 2016, 55, 1000-1008.	0.9	151
115	Improved survival in granulomatosis with polyangiitis: A general population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 483-489.	1.6	55
116	IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 2466-2475.	2.9	463
117	Rituximab for IgG4-related disease: a prospective, open-label trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1171-1177.	0.5	533
118	B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2236-2243.	0.5	120
119	An update on IgG4-related disease. <i>Current Opinion in Rheumatology</i> , 2015, 27, 83-90.	2.0	39
120	Response to: "Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4...years"™ by Yamamoto et al. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e47-e47.	0.5	3
121	Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 190-195.	0.5	409
122	Ophthalmic manifestations of IgG4-related disease: Single-center experience and literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 806-817.	1.6	182
123	De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 679-687.	1.5	302
124	IgG4-Related Disease and Hypertrophic Pachymeningitis. <i>Medicine (United States)</i> , 2013, 92, 206-216.	0.4	155
125	IgG4-Related Systemic Disease as a Cause of "Idiopathic" Orbital Inflammation, Including Orbital Myositis, and Trigeminal Nerve Involvement. <i>Survey of Ophthalmology</i> , 2012, 57, 26-33.	1.7	144
126	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. <i>Global Rheumatology</i> , 0,	0.0	10